Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Institutional

Corrections log — page 2

Every correction the Institute has made, including corrections that did not change a conclusion.

Corrections

58 documents · page 2 of 2

Table 1. Corrections on this page, in date order.

ReferenceDateCorrectionDocumentVersion increment
CEI-CR/01204 Dec 2024Provenance label addedA reconstructed value was not labelled as such and now is.Register entry: Dr Hyacinth Drakeford-AmadiYes
CEI-CR/04501 Dec 2024Terminology correctedTwo terms used interchangeably were separated, following a comment-period submission.Trial abstract: TB4-PH1-CARDIAC-REGIONAL-JPYes
CEI-CR/05029 Oct 2024Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Draft certainty indexNo
CEI-CR/03304 Oct 2024Numerical correctionA number in a table was corrected against its source.Draft synthesis: Completeness of certificates of analysis in the…Yes
CEI-CR/01801 Jul 2024Attribution correctionA result was attributed to the wrong trial and has been reattributed.Register entry: Dr Jerome LavrentievYes
CEI-CR/01121 Jun 2024Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Trial abstract: SURMOUNT-4-HEPATIC-IMPNo
CEI-CR/00610 Jun 2024Numerical correctionA number in a table was corrected against its source.Draft policy: labelling of Institute-constructed programme recordsYes
CEI-CR/04431 May 2024Numerical correctionA number in a table was corrected against its source.Draft monograph: danuglipronYes
CEI-CR/00515 May 2024Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Trial abstract: CJC-PH1-ASCENDING-BODY-COMPNo
CEI-CR/03429 Apr 2024Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Synthesis: Human evidence for BPC-157No
CEI-CR/02228 Apr 2024Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Trial abstract: SCALE-PREDIABETES-OLENo
CEI-CR/01901 Mar 2024Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Synthesis: Cardiovascular outcomes with glucagon-like peptide-1…No
CEI-CR/02827 Feb 2024Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Trial abstract: SYNCHRONIZE-1-ELDERLYNo
CEI-CR/04323 Jan 2024Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Trial abstract: TA1-VACCINE-ELDERLY-QOLNo
CEI-CR/03116 Jan 2024Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Register entry: Adaeze Underhill-OkaforNo
CEI-CR/02922 Dec 2023Provenance label addedA reconstructed value was not labelled as such and now is.Indication assessment: Inflammatory bowel disease and mucosal barrier…Yes
CEI-CR/05306 Dec 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Defined term: Karl Fischer titrationNo
CEI-CR/00824 Nov 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Trial abstract: GETGOAL-M-ADHERENCENo
CEI-CR/02720 Nov 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Register entry: Dr Ludmila Castellanos-ReidYes
CEI-CR/05624 Oct 2023Provenance label addedA reconstructed value was not labelled as such and now is.Bibliographic record: Continued treatment with tirzepatide for…Yes
CEI-CR/00708 Oct 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Trial abstract: REWINDYes
CEI-CR/03203 Oct 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Defined term: Serious adverse eventYes
CEI-CR/02005 Sep 2023Provenance label addedA reconstructed value was not labelled as such and now is.Trial abstract: ELAM-PH2-HFPEF-BIOMARKERYes
CEI-CR/02527 Aug 2023Typographical correctionA spelling or punctuation error was corrected. No conclusion was affected.Indication assessment: Hypothalamic and syndromic obesityNo
CEI-CR/04207 Aug 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Register entry: Dr Hamish Nyquist-ObioraNo
CEI-CR/05405 Aug 2023Attribution correctionA result was attributed to the wrong trial and has been reattributed.Indication assessment: Sleep initiation and maintenance disordersYes
CEI-CR/05519 Jul 2023Broken cross-referenceAn internal reference pointed at the wrong section and has been repaired.Defined term: Peptide mappingNo
CEI-CR/01702 Jun 2023Figure axis correctedA figure axis was changed to include the null following a submission that it exaggerated a difference.Trial abstract: SUSTAIN-6-BODY-COMPNo

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.